anmelden
OMX Copenhagen 20
1.544,40
PKT
+5,93
PKT
+0,39
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen 20-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 05.05.22 | Novo Nordisk Outperform | Bernstein Research | |
| 05.05.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.05.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 03.05.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 29.04.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 29.04.22 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 29.04.22 | Novo Nordisk Outperform | Bernstein Research | |
| 29.04.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 28.04.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 27.04.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 21.04.22 | Novo Nordisk Outperform | Bernstein Research | |
| 19.04.22 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 14.04.22 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 12.04.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 01.04.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 01.04.22 | Novo Nordisk Neutral | Credit Suisse Group | |
| 29.03.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 22.03.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 16.03.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 04.03.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.03.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 04.03.22 | Novo Nordisk Hold | Deutsche Bank AG | |
| 28.02.22 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 15.02.22 | Novo Nordisk Overweight | Barclays Capital | |
| 08.02.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 07.02.22 | Novo Nordisk Hold | Deutsche Bank AG | |
| 03.02.22 | Novo Nordisk Neutral | UBS AG | |
| 03.02.22 | Novo Nordisk Outperform | Bernstein Research | |
| 03.02.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 03.02.22 | Novo Nordisk Hold | Deutsche Bank AG | |
| 03.02.22 | Novo Nordisk Neutral | Credit Suisse Group | |
| 02.02.22 | Novo Nordisk Outperform | Bernstein Research | |
| 02.02.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 02.02.22 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 02.02.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 01.02.22 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 31.01.22 | Novo Nordisk Overweight | Barclays Capital | |
| 26.01.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 26.01.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 25.01.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. |